Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors.

Recombinant immunotoxins (RIT) are targeted anticancer agents that are composed of a targeting antibody fragment and a protein toxin fragment. SS1P is a RIT that targets mesothelin on the surface of cancer cells and is being evaluated in patients with mesothelioma. Mesothelin, like many other target antigens, is shed from the cell surface. However, whether… CONTINUE READING

1 Figure or Table